(300 WORDS MAX.) We will use Trisomy 21 cells to accurately model pathologies of Alzheimer's disease. These cells will be used to screen drug-like small molecules and their mixtures in order to identify agents that show disease-modifying neuroprotective properties similar to the natural growth factor BDNF. Advantages of our approach include i) disease-relevant cell based models of AD, ii) well-characterized, drug-like screening set of small molecules and iii) diversified 'fingerprint'-like insight into properties of the identified development candidates. The identified actives are expected to be immediately suitable for in vivo testing in the animal models of AD.